FDA Turns Kratom's Future In US Dietary Supplement Market Into History
This article was originally published in The Rose Sheet
FDA Commissioner Scott Gottlieb says kratom's apparently increasing use "as an alternative or adjunct to opioid use" has made enforcement on the ingredient more of a priority for FDA, and "given the scope of this crisis, we must do more."
You may also be interested in...
FDA and FTC joint warnings to four kratom firms as well as an essential oil marketer explain they're acting under Department of Health and Human Services’ declaration of a public health emergency involving the opioid crisis.
American Kratom Association didn’t convince court to order FDA to extend to deadline for comments responding to World Health Organization’s question on whether kratom should be deemed controlled substances under UN schedule. Short comment period is “latest in what we think is a very hostile action” by FDA about kratom, says AKA executive Mac Haddow.
RFP states FDA "previously warned consumers about the use of Kratom (Mitragyna speciosa)” and although botanical’s “use is prevalent, to date, clinical evaluations of abuse potential have not been performed.”